Ophthal Medical News about macular oedema

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema
Acta Ophthalmologica, 08/13/09

Querques G et al. – These findings demonstrate that selective inhibition by intravitreal pegaptanib sodium of vascular endothelial growth factor (VEGF)–165 may produce a clinically meaningful and statistically significant benefit in the treatment of DMO.

<< Previous
Aberrant Wound-Healing Response in Mitomycin C-Treated Leaking...

Next >>
Significant improvements in near vision, reading speed, central...

Associations between chronic glycosylated haemoglobin (HbA1c) level and macular volume in diabetes patients without macular oedema
Acta Ophthalmologica, 11/13/09 Relevance Score: 68%

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion
Eye, 10/06/09 Relevance Score: 67%

Improving intraocular lens power prediction in combined phacoemulsification and vitrectomy in eyes with macular oedema
Acta Ophthalmologica, 11/17/09 Relevance Score: 66%

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema
Cochrane Reviews, 10/20/09 Relevance Score: 66%

Diabetic macular oedema and visual loss: relationship to location, severity and duration
Acta Ophthalmologica, 10/12/09 Relevance Score: 65%